Phibro Animal Health Corporation (NASDAQ:PAHC) Receives Average Recommendation of “Hold” from Brokerages

Phibro Animal Health Corporation (NASDAQ:PAHC) has earned a consensus recommendation of “Hold” from the seven brokerages that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $38.80.

A number of research firms recently issued reports on PAHC. Zacks Research downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 21st. Wall Street Zen downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Weiss Ratings downgraded shares of Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 8th. Finally, Citigroup reduced their target price on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a research note on Thursday, May 14th.

Phibro Animal Health Price Performance

Shares of NASDAQ:PAHC opened at $32.43 on Monday. The company has a debt-to-equity ratio of 1.97, a quick ratio of 1.26 and a current ratio of 3.17. The firm has a fifty day moving average price of $46.18 and a 200 day moving average price of $45.14. Phibro Animal Health has a fifty-two week low of $22.85 and a fifty-two week high of $60.08. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of 13.92, a P/E/G ratio of 0.49 and a beta of 0.46.

Phibro Animal Health (NASDAQ:PAHC) last issued its earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.04. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. The firm had revenue of $383.54 million during the quarter, compared to analyst estimates of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. As a group, sell-side analysts expect that Phibro Animal Health will post 3.07 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 24th. Stockholders of record on Wednesday, June 3rd will be paid a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, June 3rd. This represents a $0.48 annualized dividend and a dividend yield of 1.5%. Phibro Animal Health’s dividend payout ratio is currently 20.60%.

Insider Buying and Selling at Phibro Animal Health

In other news, CEO Jack Bendheim sold 4,528 shares of the stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $48.49, for a total value of $219,562.72. Following the sale, the chief executive officer owned 56,152 shares of the company’s stock, valued at approximately $2,722,810.48. This represents a 7.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 74,928 shares of company stock valued at $4,017,273 over the last quarter. Corporate insiders own 50.13% of the company’s stock.

Institutional Investors Weigh In On Phibro Animal Health

Several hedge funds and other institutional investors have recently made changes to their positions in PAHC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Phibro Animal Health by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock valued at $260,000 after acquiring an additional 546 shares during the period. Millennium Management LLC raised its stake in shares of Phibro Animal Health by 74.3% in the first quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock valued at $7,733,000 after acquiring an additional 154,281 shares during the period. Jane Street Group LLC raised its stake in shares of Phibro Animal Health by 65.3% in the first quarter. Jane Street Group LLC now owns 33,917 shares of the company’s stock valued at $724,000 after acquiring an additional 13,404 shares during the period. Cetera Investment Advisers grew its holdings in shares of Phibro Animal Health by 63.0% in the second quarter. Cetera Investment Advisers now owns 18,830 shares of the company’s stock worth $481,000 after purchasing an additional 7,280 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Phibro Animal Health by 2.9% in the second quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock worth $332,000 after purchasing an additional 363 shares during the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.